Roche Invests $55 Million in Manifold Bio’s AI Technology to Develop Blood-Brain Barrier Drug Shuttles

Roche has entered into a $55 million agreement with Manifold Bio to utilize its drug discovery technology in the development of treatments targeting the brain. The collaboration focuses on creating specialized “shuttles” designed to transport medicines across the blood-brain barrier, a critical challenge in neurological drug development.

The blood-brain barrier serves as a protective shield for the brain, preventing harmful substances from entering but also posing significant obstacles for delivering therapeutic drugs. Manifold Bio’s technology leverages artificial intelligence to design and optimize these molecular shuttles, aiming to improve drug delivery efficiency and effectiveness. Roche’s investment grants access to this advanced platform, which could potentially accelerate research and innovation in addressing neurological conditions.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 3, 2025

Related posts:

CDMO Contracts: Analysis Highlights Five Key Areas to Avoid Unexpected Costs and Delays Study Identifies Cellular Network in Immune System That Enables Oral Tolerance to Foods Like Peanuts and Dairy FDA Pilots Quality Management Maturity Program to Encourage Advanced Quality Systems in Pharma Industry Sulfated Yeast Identified as Method to Extract Rare Earth Metals from Electronic Waste

Author

GOAI